Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)

PHASE3CompletedINTERVENTIONAL
Enrollment

543

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

July 31, 2019

Conditions
Colorectal Cancer MetastaticColorectal Cancer Recurrent
Interventions
DRUG

Famitinib

25 mg p.o. qd

DRUG

Placebo

25 mg p.o. qd

Trial Locations (44)

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

The Second Affiliated Hospital of Anhui Medical University, Hefei

Beijing Cancer Hospital, Peking University, Beijing

Beijing Chao-yang Hospital, Capital Medical University, Beijing

Beijing Friendship Hospital, Capital Medical University, Beijing

Chinese Academy of Medical Sciences Cancer Hospital, Beijing

PLA Hospital 301, Beijing

The Third Affiliated Hospital of The Third Military Medical University, Chongqing

Fujian Medical University Union Hospital, Fuzhou

Cancer center, Sun Yet-sen University, Guangzhou

The First Affiliated Hospital of Guangzhou Medical University of Chinese Medicine, Guangzhou

Cancer Hospital of Guangxi Zhuang Autonomous Region, Nanning

Hospital of Guangxi Zhuang Autonomous Region, Nanning

Hainan General Hospital, Hainan

Harbin Medical University Cancer Hospital, Harbin

The first affiliated hospital of Xinxiang medical university, Xinxiang

Cancer Hospital of Henan Province, Zhengzhou

The First affiliated Hospital of Zhengzhou University, Zhengzhou

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Wuhan General Hospital of Guangzhou Military, Wuhan

Cancer Hospital of Hunan Province, Changsha

The Third Xiangya Hospital of Cental South University, Changsha

The First People's Hospital of Changzhou, Changzhou

Cancer Hospital of Jiangsu Province, Nanjing

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

The Affiliated Hospital of Xuzhou Medical Collage, Xuzhou

Cancer Hospital of Jiangxi Province, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

Cancer Hospital of Jilin province, Changchun

The First Affiliated Hospital of Jilin University, Changchun

Cancer Hospital of Liaoning Province, Shenyang

Chinese Medical University First Hospital, Shenyang

Fudan University Cancer Hospital, Shanghai

Ruijin Hospital, Shanghai jiaotong University, School of Medicine, Shanghai

Shanghai General Hospital, Shanghai

Zhongshan Hospital of Fudan University, Shanghai

Cancer Hospital of Shanxi Province, Xian

Tangdu Hospital of The Fouth Military Medical University, Xian

Cancer Hospital of Tianjin City, Tianjin

People's Hospital of Tianjin City, Tianjin

Cancer Hospital of Yunnan Province, Kunming

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02390947 - Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) | Biotech Hunter | Biotech Hunter